The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
We acknowledge Lévy et al 1 for their interest in our randomized trial 2 comparing pirtobrutinib with ibrutinib in patients with treatment-naïve and relapsed/refractory (R/R) chronic lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results